HLA-B and melanoma: We describe a polyclonal CD8+ T cell response to HLA-B*07:02 presenting the immunodominant NY-ESO-160–72 peptide, which was detected in patients with melanomas expressing NY-ESO-117, an antigen of importance in onco-immunology given its tumour-dependent expression and growing importance as a therapeutic target39,43,50,51.